Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964547 | 0.91 | SCN9A (0.39) | SCN9ACYP2C19 | |
| SCHEMBL4065246 | 0.87 | SCN9A (0.42) | SCN9A | |
| SCHEMBL19827391 | 0.87 | SCN9A (0.39) | SCN9ACYP2C19 | |
| SCHEMBL6049380 | 0.81 | SCN9A (0.41) | SCN9A | |
| SCHEMBL9567022 | 0.80 | TSHR (0.35) | — | |
| SCHEMBL9350427 | 0.80 | NOTUM (0.40) | — | |
| SCHEMBL22745804 | 0.79 | MAPT (0.36) | CYP2C19 | |
| Saflufenacil SCHEMBL29349941 | 0.79 | SCN9A (0.39) | SCN9A | |
| Saflufenacil SCHEMBL712168 | 0.79 | SCN9A (0.39) | SCN9A | |
| SCHEMBL6049397 | 0.78 | SCN9A (0.34) | SCN9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653002-B2 | Aqueous suspension concentrate formulations containing saflufenacil | BASF SE (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120149577-A1 | Aqueous Suspension Concentrate Formulations Containing Saflufenacil | BASF SE (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149577-A1 | Aqueous Suspension Concentrate Formulations Containing Saflufenacil | PFAS, SKP2, PCMT1 | SCN9A 2031/4885CYP2C19 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.